Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 3/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | FABP7 | O15540 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27443673 | 0.87 | KMT2A (0.48) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL21522985 | 0.85 | KMT2A (0.57) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL27443155 | 0.85 | KMT2A (0.56) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL27443289 | 0.84 | KMT2A (0.46) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL18557550 | 0.83 | KMT2A (0.56) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL29362505 | 0.81 | KMT2A (0.54) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL29503775 | 0.81 | KMT2A (0.54) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL119779 | 0.81 | KMT2A (0.54) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL11947976 | 0.80 | KMT2A (0.53) | KMT2AEPHX2CASP3MDM4TP53 | |
| SCHEMBL15434691 | 0.80 | KMT2A (0.53) | KMT2AEPHX2CASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240269308-A1 | PRODRUGS OF TOPOISOMERASE I INHIBITOR FOR ADC CONJUGATIONS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| WO-2024138000-A1 | PRODRUGS OF TOPOISOMERASE I INHIBITOR FOR ADC CONJUGATIONS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269308-A1 | PRODRUGS OF TOPOISOMERASE I INHIBITOR FOR ADC CONJUGATIONS AND METHODS OF USE THEREOF | TOP1, TOP2A, QPCT | KMT2A 1040/4885EPHX2 2582/4885CASP3 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.